{"id":"switch-ticagrelor-to-clopidogrel","safety":{"commonSideEffects":[{"rate":"3–5","effect":"Bleeding (major and minor)"},{"rate":"null","effect":"Dyspnea"},{"rate":"null","effect":"Bradycardia"},{"rate":"1–2","effect":"Rash"},{"rate":"1–2","effect":"Gastrointestinal bleeding"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clopidogrel is a thienopyridine prodrug that requires hepatic metabolism to its active form, which then binds irreversibly to the P2Y12 receptor on platelets, preventing ADP-induced platelet activation and aggregation. This antiplatelet effect reduces thrombotic events in patients with acute coronary syndromes and other atherosclerotic conditions. The switch from ticagrelor (a reversible P2Y12 inhibitor) to clopidogrel represents a change in antiplatelet strategy, typically for reasons of cost, tolerability, or clinical judgment.","oneSentence":"Clopidogrel is a P2Y12 platelet adenosine diphosphate receptor antagonist that irreversibly inhibits platelet aggregation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:30.864Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (unstable angina, NSTEMI, STEMI)"},{"name":"Secondary prevention of atherosclerotic events in patients with prior myocardial infarction, stroke, or peripheral arterial disease"},{"name":"Coronary artery disease managed with percutaneous coronary intervention"}]},"trialDetails":[{"nctId":"NCT05681702","phase":"PHASE4","title":"Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI","status":"RECRUITING","sponsor":"University of Florida","startDate":"2023-02-15","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT07432516","phase":"NA","title":"Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-02","conditions":"Coronary Artery Disease","enrollment":4400},{"nctId":"NCT06588595","phase":"PHASE4","title":"The Switching Antiplatelet-9 (SWAP-9) Study","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-11-01","conditions":"Coronary Arterial Disease (CAD)","enrollment":90},{"nctId":"NCT05531474","phase":"NA","title":"Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2020-11-02","conditions":"Cardiovascular Complication, Bariatric Surgery Candidate","enrollment":200},{"nctId":"NCT06228456","phase":"PHASE4","title":"Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-04-01","conditions":"Coronary Artery Disease","enrollment":50},{"nctId":"NCT06759272","phase":"PHASE4","title":"Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients","status":"NOT_YET_RECRUITING","sponsor":"Nur Hafizah Annezah binti Utuh","startDate":"2025-02","conditions":"Coronary Arterial Disease (CAD), ACS (Acute Coronary Syndrome), SCAD","enrollment":120},{"nctId":"NCT04937699","phase":"PHASE4","title":"Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-28","conditions":"Acute Coronary Syndrome, Percutaneous Coronary Intervention","enrollment":2690},{"nctId":"NCT04006288","phase":"PHASE4","title":"Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-09-06","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT04116931","phase":"PHASE4","title":"OPTImal Management of Antithrombotic Agents: OPTIMA-5","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-06-22","conditions":"Acute Coronary Syndrome (ACS)","enrollment":80},{"nctId":"NCT02091921","phase":"PHASE1, PHASE2","title":"Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2014-02-16","conditions":"Critical Limb Ischemia","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["switch"],"phase":"marketed","status":"active","brandName":"Switch ticagrelor to clopidogrel","genericName":"Switch ticagrelor to clopidogrel","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clopidogrel is a P2Y12 platelet adenosine diphosphate receptor antagonist that irreversibly inhibits platelet aggregation. Used for Acute coronary syndrome (unstable angina, NSTEMI, STEMI), Secondary prevention of atherosclerotic events in patients with prior myocardial infarction, stroke, or peripheral arterial disease, Coronary artery disease managed with percutaneous coronary intervention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}